Internal correspondence reveals Coinbase co-founder Fred Ehrsam was personally briefed on and facilitated a multi-million dollar investment from the convicted sex offender, arranged by Tether's Brock Pierce.
Thai troops now occupy a shell-damaged compound in O'Smach, Cambodia, which officials identify as a former hub for international scam operations. A military-led tour revealed a labyrinth of soundproofed call centers, fake police stations, and meticulous scripts, shedding light on a multi-billion dollar criminal enterprise.
A damning report from the EU's financial watchdog reveals the bloc's struggle to secure the minerals essential for its climate goals, highlighting failed trade deals, stalled recycling, and persistent over-reliance on external suppliers.
Once a high-flying green energy IPO, Plug Power now trades near historic lows. While its technology powers giants like Amazon and Walmart, mounting losses and a shifting political landscape pose existential questions about its path to profitability.
Tesla's stock dipped amid reports of potential Ford-Xiaomi joint venture talks, highlighting growing competitive pressures from Chinese EV makers and the complex geopolitical landscape shaping the auto industry's future.
ExxonMobil has commenced commercial operations at a significant carbon capture and storage (CCS) facility in Louisiana, developed in partnership with CF Industries. The move signals a strategic expansion of the oil giant's low-carbon portfolio and has sparked debate among investors weighing its long-term value against current momentum.
A Nevada judge has barred prediction market platform Polymarket from operating in the state, leaning on recent federal rulings against similar platforms. The decision marks a significant setback for the company's regulated U.S. relaunch and underscores the ongoing legal tension between state gambling laws and federal commodities regulations.
Despite recent volatility in silver prices, Wheaton Precious Metals' unique streaming model positions it to generate robust cash flow, making it a standout choice for exposure to the precious metal.
A damning report from the European Court of Auditors reveals the bloc is falling dangerously behind in securing the lithium, cobalt, and nickel needed for its energy transition, leaving climate goals and strategic autonomy in jeopardy.
Prominent crypto analyst Tom Lee faces a wave of skepticism after his aggressive price predictions for Ethereum and Bitcoin fail to materialize amid a market downturn, sparking debate over the role of high-profile forecasts in volatile markets.
A discounted cash flow analysis suggests Savaria Corporation's stock may be trading significantly below its intrinsic value, presenting a potential opportunity for investors. However, experts caution that valuation models are only one piece of the investment puzzle.
Target's Michael Fiddelke and Walmart's John Furner step into the CEO role, outlining priorities to reinvigorate growth and customer loyalty amid operational and social challenges.
Hawxhurst LLP has filed a federal lawsuit against International Amusement Rides and Intamin Ltd., alleging the roller coaster manufacturers failed to pay $1.5 million in legal fees after the firm defended them in high-stakes intellectual property battles.
After years of share price weakness, Immunocore Holdings (IMCR) appears significantly undervalued by traditional metrics. But does the market know something the models don't? We examine the DCF and P/S analyses, the company's unique T-cell receptor platform, and the risks that have kept investors wary.
Shares of clinical-stage biotech Scholar Rock (NASDAQ: SRRK) have surged nearly 60% in three months, closing at $44.34. This rally, backed by promising clinical progress, has investors weighing its premium valuation against its long-term potential in treating serious diseases.
Analyst Piper Sandler has lowered its price target on Black Diamond Therapeutics (BDTX) while maintaining an Overweight rating, following a broad review of its biotech coverage. The adjustment comes even as the company recently reported encouraging Phase 2 data for its lead oncology drug candidate.
Former UK ambassador to Washington, Peter Mandelson, faces intensifying political and public pressure to relinquish his lifetime seat in the House of Lords following new revelations about his financial and personal ties to the late convicted sex offender Jeffrey Epstein. Prime Minister Keir Starmer has called for his resignation, as documents suggest payments and close correspondence between the two.
Garrett Motion (GTX) is drawing strong buy ratings from analysts, with a median price target suggesting over 20% upside, driven by its strategic pivot to zero-emission vehicle technologies and resilient financial profile.
H.C. Wainwright maintains a Buy rating on Lexeo Therapeutics but slashes its price target, citing persistent market doubts over the company's PKP2 cardiomyopathy program despite encouraging early clinical results.
Barclays initiates coverage of 4D Molecular Therapeutics with an Overweight rating and a $33 price target, citing a favorable industry backdrop with potential M&A tailwinds and shifting focus away from drug pricing pressures. The gene therapy developer also outlined key clinical milestones expected through 2026.
